Reading VTAK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTAK free→Reading VTAK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTAK free→QuarterlyIQ Insights · VTAK
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. Purchase Agreement On June 7, 2026, Catheter Precision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) between Volato Group, Inc. (NYSE American: SOAR), a Delaware corporation (“Volato”), the Company, and other investors party thereto, pursuant to which the Company agreed to purchase 2,941,176 shares of common stock, par value $0.0001 per share, of Volato (“Shares”) at a per share purchase price of $0.34…
Results of Operations and Financial Condition. On May 18, 2026, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section…
Material Modification to Rights of Security Holders. The information set forth under
Unregistered Sales of Equity Securities. Issuance of Series C-2 Convertible Preferred Stock On April 21, 2026, Catheter Precision, Inc. (the “Company”) consummated the closing (the “Series C-2 Closing”) of its previously disclosed sale and issuance of an aggregate of 3,470 shares of the Company’s newly designated Series C-2 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the “Series C-2 Preferred Stock”), for aggregate gross proceeds of $3,470,00…
Results of Operations and Financial Condition. On March 31, 2026, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of…
Entry into a Material Definitive Agreement. Private Placement Financing Securities Purchase Agreement On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of 1,853 shares of the Company’s Series C-1 Convertible Preferred Stock, with a par va…
Unregistered Sales of Equity Securities. The matters described in
Material Modification to Rights of Security Holders. The information contained in
Unregistered Sales of Equity Securities. All information set forth in
Entry into a Material Definitive Agreement. On February 12, 2026, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into Series J Exchange Agreements (the "Exchange Agreements") with David A. Jenkins and FatBoy Capital, LP. (the "Holders") to convert royalty rights and accrued royalty right amounts into 2,491.293 shares and 6,998.195 shares, respectively of the Company's newly created Series J Convertible Preferred Stock, with a par value of $0.0001 per share and a sta…
Material Modification to Rights of Security Holders. The matters described in
Unregistered Sales of Equity Securities. The matters described in
Entry into a Material Definitive Agreement. Private Placement Financing Securities Purchase Agreement On February 6, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of (i) 392,608 shares of the Company’s common stock, par value $0.0001 per share (“…
Entry into a Material Definitive Agreement. Second Amendment to Short Term Promissory Notes On December 31, 2025, Catheter Precision, Inc. (the “Company”) amended each of its currently outstanding 8% Short Term Promissory Notes (the “Notes”) identified in the table below, each of which had a previously amended Maturity Date of January 31, 2026, to extend the maturity date as set forth in the table below. The amendments were each memorialized by a Second Amendment to 8% Short Term Promissory N…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure in
Termination of a Material Definitive Agreement. On November 17, 2025, Catheter Precision, Inc. (the “Company”) delivered notice to terminate its At-Market-Offering Agreement (the “ATM Agreement”), dated as of May 19, 2025, with Ladenburg Thalmann & Co. Inc. (the “Agent”) providing for the Company’s “at‑the‑market” equity offering program (the “ATM Program”), to be effective as of November 24, 2025. Pursuant to the ATM Agreement and the prospectus supplements filed for the ATM Program, the Com…
Results of Operations and Financial Condition. On November 13, 2025, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the pu…
Other Events. This Form 8-K is being filed for the purpose of filing the legal opinion of Arnall Golden Gregory LLP dated August 18, 2025 in connection with the Prospectus Supplement dated August 7, 2025 of Catheter Precision, Inc. (the “Company”), in order that it may be incorporated by reference into the Company’s Registration Statement on Form S-3 (Registration No. 333-284217). Also, the Company issued a press release on August 18, 2025 regarding approval of its LockeT product in Great Bri…
Material Modification to Rights of Security Holders. To the extent required by
Results of Operations and Financial Condition. On August 11, 2025, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes o…
Other Events. Catheter Precision, Inc. (VTAK) (the “Company”) today announced a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of one (1) share of common stock for every nineteen (19) shares of common stock outstanding, that will become effective as of 12:01 a.m. (Eastern Time) on August 15, 2025 (the “Effective Date”). The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on August 15,…
Other Events. This Form 8-K is being filed for the purpose of filing the legal opinion of Arnall Golden Gregory LLP dated June 13, 2025 in connection with the Prospectus Supplement dated June 13, 2025 of Catheter Precision, Inc. (the “Company”), in order that it may be incorporated by reference into the Company’s Registration Statement on Form S-3 (Registration No. 333-284217). Also, the Company issued a press release on June 12, 2025 regarding recent sales and sales trajectory of its LockeT…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 2, 2025, Catheter Precision, Inc. (the “Company”) discontinued the employment of Marie-Claude Jacques, the Company’s Chief Commercial Officer. Mr. David Jenkins, the Company’s Executive Chairman of the Board and Chief Executive Officer, will fill the role of Chief Commercial Officer until a replacement is engaged. SIGNATURES Pursuant to the…
Entry into a Material Definitive Agreement. At the Market Offering Agreement On May 19, 2025, Catheter Precision, Inc. (the “Company”) entered into an At Market Offering Agreement (the “Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). Under the Agreement, the Company may offer and sell its common stock, par value $0.0001 per share, from time to time the maximum amount permissible under Securities and Exchange Commission rules, currently $1.3 million (the “Shares”), during the ter…
Results of Operations and Financial Condition. On May 14, 2025, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of…
Importance-ranked changes since the prior daily snapshot.
Management rose by 12.2 points (from 7.6 to 19.8).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.